Biocartis, SkylineDx Partner to Develop Melanoma Nodal Metastasis Risk Test

Source: genomeweb, April 2021

Biocartis said on Thursday that it has partnered with Rotterdam, Netherlands-based SkylineDx to develop that firm’s Merlin assay to predict a melanoma patient’s risk of nodal metastasis on Biocartis’ Idylla platform.

SkylineDx will lead development of the Merlin assay on Idylla, expected to start this year, while Biocartis, based in Belgium, will commercialize the assay in Europe through its Idylla network.

SkylineDx’s Merlin assay integrates gene expression data with a patient’s age and tumor thickness to reduce the number of unnecessary sentinel lymph node biopsy surgeries.

READ THE ORIGINAL FULL ARTICLE